Alcohol Withdrawal Syndrome

Definition

Alcohol withdrawal syndrome (AWS) is the clinical syndrome that occurs when a person with alcohol dependence or alcohol use disorder abruptly reduces or stops alcohol consumption ^[8]B3b. In clinical and research settings, AWS is therefore a syndrome-based diagnosis rather than a designation based solely on a positive blood alcohol level, a history of alcohol use, or an administrative code ^{[2]B3b[3]B2c[8]B3b}. Hospitalized patients with alcohol dependence are at risk of developing AWS during admission, including patients who do not initially present with withdrawal ^[8]B3b.

The available evidence uses DSM-5 terminology for alcohol withdrawal: AWS was classified as present when patients with alcohol use disorder experienced at least 2 clinical signs or symptoms and/or reported the relevant withdrawal experience described in the DSM-5 criteria ^[4]B3b. Because the supplied study evaluated patients entering treatment for alcohol use disorder, this operational definition should not be treated as a universal bedside threshold for every hospitalized patient ^[4]B3b.

Classification by clinical recognition and timing

For hospital epidemiology, AWS may be described as either present on admission or developing later during hospitalization ^[8]B3b. The distinction is clinically important because admission screening and repeated observation address different problems: some patients manifest withdrawal at presentation, whereas others develop it after the hospital encounter has begun ^[8]B3b. In a national Veterans Health Administration analysis, “clinically recognized inpatient AWS” was identified through documented diagnoses and/or procedure codes recorded at admission, transfer, or discharge ^[3]B2c. The authors found that documented prevalence varied by geographic region, hospital, admitting specialty, and inpatient diagnoses, indicating that recorded AWS is influenced by recognition and documentation as well as by patient factors ^[3]B2c.

AWS is also encountered in trauma populations. Trauma patients may have measurable blood alcohol concentrations while simultaneously being at risk for, or developing, AWS; trauma studies therefore distinguish groups by blood alcohol level and by an AWS classification rather than treating alcohol exposure and withdrawal as interchangeable terms ^[2]B3b. A history of traumatic brain injury is particularly relevant to nomenclature and assessment because TBI and AWS can produce overlapping signs and symptoms, while their treatment strategies differ ^[119]C.

Classification by severity and treatment-relevant phenotype

The supplied literature supports several treatment-relevant descriptors. “Severe AWS” is used for patients requiring intensive monitoring or escalation of treatment, including those managed in an intensive care unit ^[7]B3b[9]B3b. “Resistant alcohol withdrawal” (RAW) denotes a subset of patients whose withdrawal does not respond to benzodiazepines despite escalating doses ^[9]B3b. RAW is associated with greater use of mechanical ventilation, more nosocomial pneumonia, and longer ICU stays ^[9]B3b. These terms should be viewed as severity or response-to-treatment descriptors, not as substitutes for the underlying diagnosis of AWS.

“Delirium tremens” (DT) is used as a separate diagnostic label in hospital studies and may be recorded together with AWS; one inpatient protocol study included patients discharged with either an AWS or DT diagnosis ^[1]B3b. The supplied references do not provide a sufficiently detailed clinical definition to equate DT automatically with every case of severe or resistant AWS. Accordingly, DT should be retained as a distinct clinical nomenclature term when documented, while severity and treatment resistance should be stated separately when supported ^[1]B3b[9]B3b.

Classification by assessment and management language

“Symptom-triggered,” “fixed-dose,” and “front-loading” describe benzodiazepine treatment strategies rather than AWS subtypes ^[5]B2c. In a national cohort of 6,938 medical inpatients treated for AWS, 41.9% received symptom-triggered treatment, 40.8% fixed-dose treatment, and 17.3% front-loading treatment ^[5]B2c. A hospital-wide CIWA-Ar protocol likewise represents a symptom-based management approach, not a new diagnostic category ^[6]B3b.

The Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), is a structured instrument that grades withdrawal signs and symptoms and is used to guide addition or titration of central nervous system depressants, most commonly benzodiazepines ^[119]C. A simplified derivative, the Highland Alcohol Withdrawal Protocol, was evaluated as a symptom-triggered tool for hospitalized patients with AWS or DT ^[1]B3b. CIWA-based scores should therefore be understood as assessment or treatment-guidance measurements, not as stand-alone definitions of AWS ^{[1]B3b[6]B3b[119]C}.

Admission risk screening is related but distinct from diagnosis. The AUDIT-PC was evaluated for predicting subsequent AWS among hospitalized medical-surgical patients, but the study noted that hospitals lacked a validated tool for identifying withdrawal risk at the time ^[8]B3b. Thus, an alcohol-use screening score may support risk stratification but does not itself establish AWS ^[8]B3b.

Related complications and associated findings

Arrhythmias, including atrial arrhythmias, are documented complications or associated findings during AWS hospitalization rather than alternative names for AWS ^[120]D. In a nationwide analysis of approximately 1.5 million AWS hospitalizations, arrhythmias were associated with increased mortality ^[120]D. Their presence should consequently be documented separately from the withdrawal diagnosis ^[120]D.

Core neuroadaptation

Alcohol withdrawal syndrome (AWS) is characterized clinically by central nervous system hyperexcitation after alcohol intake is reduced or stopped. The clinical spectrum may progress from early autonomic and subjective symptoms to hallucinations, seizures, and delirium tremens. ^[22]D5 The principal neurobiological model described in the supplied evidence is an imbalance between inhibitory γ-aminobutyric acid (GABA) signaling and excitatory glutamatergic signaling, particularly through N-methyl-D-aspartate (NMDA) pathways. ^{[17]A1b[22]D5[123]D[124]D} During ongoing alcohol exposure, compensatory neuroadaptation is thought to maintain network stability; when alcohol is withdrawn, these compensations become functionally unopposed, producing excessive neuronal excitability. This mechanism is supported clinically by the use of medications with GABAergic activity and by investigation of agents that reduce glutamatergic activity or block NMDA overactivation. ^{[17]A1b[22]D5[23]D5}

The glutamatergic component is clinically important because AWS has been associated with increased central NMDA glutamate transmission. ^[17]A1b Dextromethorphan, a low-affinity, noncompetitive NMDA antagonist with potential neuroprotective properties, nevertheless failed to demonstrate efficacy in a preliminary randomized, double-blind, placebo-controlled trial of moderate AWS. ^[17]A1b Thus, NMDA overactivity is a plausible component of withdrawal pathophysiology, but NMDA antagonism alone has not been shown to reliably control acute AWS. ^[17]A1b Propofol provides another mechanistic example: it acts as a sedative-hypnotic through GABA-A receptor agonism at a binding site distinct from that of benzodiazepines and also reduces glutamatergic activity through NMDA receptor blockade. ^[23]D5

Inhibitory signaling and metabolic cofactors

The supplied literature identifies inadequate inhibitory GABAergic signaling as a central feature of AWS. ^[123]D Pyridoxal-5′-phosphate, the active form of vitamin B6, is an essential cofactor for glutamic acid decarboxylase, the rate-limiting enzyme that converts glutamate to GABA. ^[123]D Deficiency of pyridoxal-5′-phosphate is reported to be prevalent among people with alcohol use disorder and could theoretically worsen the glutamatergic/GABAergic imbalance. ^[123]D However, the proposal that pyridoxine or pyridoxal-5′-phosphate repletion improves AWS outcomes remains a hypothesis rather than established clinical evidence. ^[123]D

Baclofen has been studied as a pharmacological means of reducing withdrawal-related hyperexcitability. A randomized comparative study enrolled 37 patients and compared baclofen, administered at 30 mg/day for 10 days, with diazepam administered for 10 days with dose tapering from day 7. ^[15]A1b The Cochrane reviews assessed baclofen for AWS across successive updates through June 2019 and describe it as a potentially useful, readily managed treatment, but the reviews were conducted to assess efficacy and safety rather than to establish a definitive neurobiological mechanism. ^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a} Baclofen is reported to produce little euphoria or drug craving in the reviewed AWS studies, although this observation does not establish superiority over benzodiazepines or replace standard supportive and pharmacological care. ^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a}

Autonomic and cardiovascular mechanisms

Autonomic activation is a prominent component of acute AWS. Propranolol studies found withdrawal-related differences in both peripheral and central β-adrenergic responses compared with remission. ^[19]C4 In alcohol-dependent subjects, the negative chronotropic and hypotensive effects of a 40-mg propranolol dose differed during withdrawal and remission; the baseline hemodynamic state was the strongest modifier of response, while the amount of daily alcohol consumption also predicted response to some extent. ^[19]C4 These findings support altered β-adrenergic physiology during withdrawal but do not demonstrate that β-adrenergic blockade corrects the underlying central excitatory state. ^[19]C4

Acute, severe, and refractory withdrawal

In severe AWS, the imbalance between inhibitory and excitatory neurotransmission may remain clinically evident despite benzodiazepine treatment, particularly as delirium in intensive-care patients. ^[109]A1a Dexmedetomidine has therefore been evaluated as an adjunct to benzodiazepine-based therapy for ICU delirium associated with AWS, rather than as a replacement for therapy directed at the core withdrawal process. ^[109]A1a GHB and clomethiazole have also been compared in a randomized open study of 26 medically ill ICU patients with severe AWS, while oxazepam and clomethiazole have been compared retrospectively in a larger clinical cohort. ^[18]A1b[121] These studies demonstrate therapeutic heterogeneity but do not by themselves resolve the underlying neurobiology. ^[18]A1b[121]

Levetiracetam plus tiapride was evaluated in an open-label outpatient case series of 9 alcohol-dependent patients treated for up to 7 days with flexible doses of up to 2,500 mg/day and 300 mg/day, respectively. ^[117]C4 Gabapentin has likewise been examined as a high-dose taper intended to reduce benzodiazepine exposure, although the available inpatient evidence is retrospective and limited. ^[122] These observations suggest that several non-benzodiazepine agents may influence withdrawal symptoms, but they should not be interpreted as proof of a single alternative neurobiological pathway. ^[117]C4[122]

Post-acute withdrawal and persistent neuroadaptation

Post-acute or protracted alcohol withdrawal reflects symptoms that continue beyond the expected acute withdrawal period. ^[16]D5[20]D5 A mixed-studies systematic review of 27 studies found that post-acute withdrawal is dominated by negative affect, including anxiety, dysphoria, anhedonia, irritability, sleep disturbance, cognitive impairment, and craving; symptoms may begin in early abstinence and persist for 4–6 months or longer. ^[16]D5 These symptoms have been associated with recurrent alcohol consumption and may therefore contribute to relapse risk. ^[16]D5 The proposed mechanisms include persistent neuroadaptive changes in GABA and NMDA systems, although protracted withdrawal remains incompletely defined and is not yet supported by a fully validated biological model. ^[20]D5[124]D

Emerging work has also implicated the sigma-1 receptor system, based primarily on preclinical evidence. Sigma-1 receptor antagonists have reduced alcohol intake, alcohol-seeking behavior, and motivation to drink in animal models and have shown potential effects on cognitive, motor, and relapse-like abnormalities. ^[20]D5 Their role in human AWS remains investigational, and current evidence does not establish sigma-1 signaling as a routine diagnostic or therapeutic target. ^[20]D5

Overview and case ascertainment

Alcohol withdrawal syndrome (AWS) is a clinically recognized complication of alcohol use disorder (AUD) and a common reason for emergency or inpatient care. Recent evidence is derived predominantly from retrospective hospital, emergency-department, trauma, and specialty-unit cohorts rather than population-based surveillance, so reported frequency is highly dependent on case definitions and the clinical setting. ^[127][128] Definitions have included diagnostic coding, clinical assessment, and the use of sedative medication to control withdrawal symptoms; in patients with alcohol-associated hepatitis, AWS was specifically defined by clinical criteria plus sedative treatment. ^[30]B2b Hospital protocols commonly identify and follow AWS using the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar), or alternative symptom scales such as the Minnesota Detoxification Scale. ^[6]B3b[130]

Epidemiology

A large United States emergency-department study evaluated AWS presentations from 2016 through 2023 using Epic Cosmos data and ICD-10 codes, assessing the proportion of all emergency visits, admission rates, length of stay, and medications administered. ^[127] A separate population-based cohort used Kaiser Permanente Washington electronic-health-record and claims data from July 1, 2018, through June 30, 2022, among adults with at least one primary-care encounter and standardized alcohol screening; it was designed to estimate the incidence and proportional incidence of hospitalizations involving AWS across patient characteristics. ^[128] These studies address different denominators—emergency visits versus a screened primary-care population—and should not be treated as interchangeable prevalence estimates. ^[127][128]

AWS is also encountered in selected high-risk inpatient populations. A multinational retrospective cohort from five medical centers in Spain and the United States included patients hospitalized with alcohol-associated hepatitis between January 2016 and January 2021 and examined AWS prevalence, predictors, management, and mortality. ^[30]B2b In Japan, a retrospective study assessed 88 patients hospitalized with alcoholic hepatitis, including the occurrence of delirium tremens (DT), associated risk factors, and outcomes. ^[40]C4 In a tertiary alcohol-related disease unit, 907 patients with AUD were studied over 2004–2022; 238 (26.2%) were female, permitting evaluation of sex-specific clinical and psychiatric features, including AWS. ^[125] Another cohort included 16,190 hospitalizations representing 10,092 patients aged 21 years or older, of whom 30.2% were women, and examined age- and sex-related AWS manifestations and hospital course. ^[36]B2b

Trauma admissions represent another clinically important setting. A Level I trauma-center study reviewed 1,011 adults with blood-alcohol-concentration testing to identify conditions associated with AWS; patients with traumatic brain injury and Glasgow Coma Scale scores of 8 or less were excluded. ^[31]B2b Psychiatric inpatient populations also contribute to the burden: one study evaluated 138 patients admitted for psychiatric reasons who were considered at risk for AWS. ^[135] Hospital-management cohorts further illustrate the range of settings in which AWS is treated, including general medical wards, intensive care units, surgical-trauma ICUs, and emergency departments. ^{[6]B3b[28]A1a[114]B3b[126][130][131][133][134]}

Etiology and clinical context

The immediate cause of AWS is interruption or substantial reduction of alcohol exposure in a person who has developed physiological dependence; the supplied studies operationalize this syndrome clinically rather than by a single laboratory test. ^{[30]B2b[31]B2b} AUD is the principal underlying disorder represented in the available cohorts. AUD has been reported to affect up to 10.7% of the European population, with historically greater prevalence among male patients, although contemporary studies specifically examine women and sex-related differences. ^[125] Alcohol-associated hepatitis and alcoholic hepatitis are important contexts because patients may be simultaneously vulnerable to withdrawal, hepatic disease severity, delirium, and death. ^{[30]B2b[40]C4}

Risk factors and high-risk groups

The evidence supports heightened clinical vigilance in patients with heavy alcohol exposure, recent hospitalization for alcohol-related disease, alcohol-associated or alcoholic hepatitis, trauma, psychiatric admission, and critical illness. ^{[30]B2b[31]B2b[40]C4[135]} In the trauma study, “heavy drinking” was defined as daily drinking or more than 7 drinks per week; the investigation was designed to combine risk conditions into screening strategies for the probability of AWS. ^[31]B2b Disease severity and demographic variables were included in multivariable analyses of patients with alcohol-associated hepatitis, indicating that both alcohol-related illness burden and patient characteristics may influence outcomes among those who develop AWS. ^[30]B2b

Age and sex are relevant epidemiologic dimensions. The large hospital cohort categorized patients as 21–39, 40–64, 65–74, and 75 years or older, using the 40–64-year group as the reference because it was the largest. ^[36]B2b Sex-specific analyses have included psychiatric comorbidity, alcohol-related cognitive impairment, cardiovascular disease, and AWS severity, rather than assuming that findings from predominantly male cohorts apply equally to women. ^[125] However, the available studies are observational and drawn from selected healthcare populations; they cannot establish that age, sex, hepatitis, trauma, or psychiatric admission independently causes AWS. ^{[30]B2b[31]B2b[36]B2b[125]}

Evidence limitations

Most available studies focus on treatment protocols or outcomes rather than incidence and etiology, including investigations of dexmedetomidine, anticonvulsants, phenobarbital, gabapentin, CIWA-Ar, and MINDS-based pathways. ^{[28]A1a[32]A1a[114]B3b[126][129][130][131][133][134]} Their results may be affected by referral patterns, coding practices, prophylactic medication, differing thresholds for admission, and inconsistent recognition of withdrawal. ^{[6]B3b[28]A1a[30]B2b[127][128]} Accordingly, AWS should be regarded as common and clinically consequential in alcohol-related hospital populations, while exact population prevalence and universally applicable predictors remain uncertain. ^{[30]B2b[127][128]}

Overview

Alcohol withdrawal syndrome (AWS) is a clinically heterogeneous disorder that can occur after cessation or substantial reduction of alcohol exposure in people with alcohol use disorder. Its severity ranges from mild symptoms to severe, potentially fatal illness, with morbidity and mortality concentrated among patients with chronic, heavy alcohol consumption and complicated withdrawal ^{[46]A1a[52]A1b}. Most patients who develop withdrawal experience a mild course, whereas a smaller proportion develop withdrawal seizures or delirium tremens (DT) ^[137].

Clinical phases and symptom domains

AWS has been described as comprising acute, early, and protracted phases ^[47]A1a. The acute and early phases are characterized by autonomic, neuropsychiatric, and neurologic manifestations that may progress in severity. Symptoms commonly assessed in clinical studies include anxiety, depressive symptoms, agitation or delirium, and seizure occurrence ^{[61]A1b[137][139]C}. Anxiety and depression may persist during treatment and are clinically relevant dimensions of withdrawal rather than merely comorbid symptoms ^[61]A1b.

Protracted alcohol withdrawal (PAW) may persist for weeks, months, or even years after drinking cessation ^[47]A1a. The best-described PAW manifestations are craving, sleep disturbance, and anhedonia ^[47]A1a. In a systematic review, craving measured with the Obsessive Compulsive Drinking Scale decreased progressively from a pooled baseline score of 24.2 to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months, indicating improvement over time but persistence beyond the initial withdrawal period ^[47]A1a.

Severity spectrum and complicated withdrawal

Severity assessment should distinguish uncomplicated withdrawal from complicated AWS. In a randomized study of alcohol-dependent outpatients with uncomplicated AWS, enrollment required a baseline Clinical Institute Withdrawal Assessment for Alcohol–revised (CIWA-Ar) score consistent with withdrawal; in a separate inpatient trial, participants were required to have a CIWA-Ar score >8, illustrating the use of this threshold to identify at least clinically meaningful withdrawal in research settings ^{[49]A1b[52]A1b}. CIWA-Ar scores quantify current symptom burden but do not, by themselves, reliably predict which patients will later develop severe or complicated withdrawal ^[50]B2a.

Complicated AWS is clinically defined by the emergence of major neurologic or delirious complications. Severe alcohol withdrawal models include DT, withdrawal seizure, or the need for high-dose benzodiazepine therapy as components of a severe-outcome composite ^[137]. Alcohol-related seizures are among the most important consequences of AWS and have been specifically evaluated for their relationship to DT and overall withdrawal severity ^[139]C. Because seizures and DT may occur in only a minority of patients but carry substantial clinical risk, early recognition of historical and objective risk factors is important ^[50]B2a[137].

Risk stratification tools have been developed for different purposes. The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was created to identify patients at risk for moderate-to-severe or complicated withdrawal, whereas CIWA-Ar is primarily a measure of current symptom severity ^[50]B2a. The Alcohol Withdrawal Triage Tool (AWTT) was derived to predict severe AWS and hospital-admission needs using objective information available during an emergency-department evaluation ^[137]. Machine-learning models have also been investigated for separating mild from moderate-to-severe withdrawal and for predicting DT and withdrawal seizures, although these approaches remain prediction tools rather than descriptions of individual symptoms ^[93]B2c.

Important complications and mimics

AWS may coexist with or be confused with other acute medical conditions. In patients with traumatic brain injury, AWS and brain injury can produce overlapping signs and symptoms, while the treatment implications differ; consequently, CIWA-Ar scores may be difficult to interpret in this population ^[119]C. Seizures in a patient with alcohol use should not automatically be attributed to withdrawal because alcoholic patients may present with serious alternative diagnoses. In a population-based study of alcoholic patients with community-acquired bacterial meningitis, 18% presented with seizures and 23% had coexisting pneumonia; alcoholic patients represented 6% of all meningitis episodes in the cohort ^[48]B2b.

Respiratory and infectious complications are also clinically relevant during severe AWS. Pneumonia risk has been specifically studied in hospitalized patients with acute AWS, including the association between low sarcopenia index and pneumonia ^[132]C. In an intensive-care cohort treated with high-dose intravenous sedatives without routine immediate intubation, pneumonia and endotracheal intubation were important outcomes, underscoring the need for close monitoring when severe agitation, delirium, or refractory symptoms require substantial sedation ^[138]C.

Nutritional deficiency can produce manifestations that overlap with AWS. Alcohol-related pellagra may present with skin lesions, diarrhea, or mental disorders, and the classic triad may be absent, making misdiagnosis possible ^[51]C4. Chronic pain is also clinically relevant because alcohol use and withdrawal may interact with pain perception; people with alcohol use disorder are more likely to experience chronic pain, and alcohol used for analgesia may be followed by acute tolerance and withdrawal-related worsening of pain ^[29]D5.

Diagnosis requires ≥2 symptoms (e.g., tremor, tachycardia, insomnia) after reducing intake ^[56]A1c. Workup must rule out mimics like meningitis , hypoglycemia , or Wernicke encephalopathy ^{[48]B2b[53]A1c}. CIWA-Ar is the gold standard for monitoring severity ^[55]A1a. PAWSS score ≥4 has a likelihood ratio (LR) of 174 for severe withdrawal ^[27]A1a.

Pearl: A PAWSS score of 4 or more is the most robust predictor of severe withdrawal (LR 174), and its use should trigger aggressive prophylaxis or ICU-level monitoring ^[27]A1a.

Clinical severity spectrum

Alcohol withdrawal syndrome (AWS) is clinically heterogeneous, ranging from autonomic symptoms and tremor to seizures, hallucinations, delirium, and potentially life-threatening complications; the 2020 American Society of Addiction Medicine (ASAM) guideline applies to adults hospitalized with AWS of any severity. ^[65]A1c Severity should therefore be assessed dynamically rather than inferred from a single symptom score, because symptoms and treatment requirements may evolve during hospitalization. ^{[55]A1a[65]A1c}

The Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) is widely used to quantify symptom burden and follow response to treatment. ^[55]A1a In an inpatient randomized trial, enrollment required a baseline CIWA-Ar score greater than 8, illustrating its use to identify clinically active withdrawal. ^[52]A1b However, CIWA-Ar is a symptom-rating instrument rather than a direct predictor of complications; patients who are delirious, sedated, intubated, cognitively impaired, or unable to communicate may require alternative clinical assessment and closer monitoring. ^[65]A1c

Course specifiers should document the most severe manifestation observed, including uncomplicated withdrawal, withdrawal-related seizure, hallucinosis, or delirium tremens (DT). ^[65]A1c A history of severe or complicated withdrawal is particularly important because current symptom intensity may underestimate subsequent risk. ^[65]A1c Treatment response, cumulative sedative requirements, persistent autonomic instability, and progression to delirium or seizure should be recorded as part of the clinical course. ^[65]A1c[144]

Risk stratification

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is used prospectively to identify patients at risk for complicated withdrawal. ^[65]A1c In a randomized hospital study, patients with PAWSS ≥4 were defined as having risk of complicated withdrawal and were randomized to fixed-dose gabapentin or symptom-triggered benzodiazepines. ^[70]B2b A PAWSS-based screening and treatment protocol was also implemented in a hospital-wide observational study, with patients at risk receiving further assessment using the Glasgow Modified Alcohol Withdrawal Scale (GMAWS). ^[143]

Risk assessment should integrate prior withdrawal complications, current alcohol-use pattern, coexisting medical illness, examination findings, laboratory abnormalities, and the reliability of monitoring. ^[65]A1c Trauma populations require particular attention: a retrospective Level I trauma-center study evaluated combinations of clinical risk conditions to estimate the probability of AWS, while excluding patients with severe traumatic brain injury defined by Glasgow Coma Scale ≤8. ^[31]B2b Another trauma case-control study examined alcohol exposure and AWS in relation to hospital outcomes, underscoring that withdrawal risk and alcohol-related illness may affect outcomes independently of the presenting injury. ^[2]B3b

Medical comorbidity can modify both severity and management. In a multinational retrospective cohort of hospitalized patients with alcohol-associated hepatitis, investigators evaluated AWS prevalence, predictors, treatment, and mortality while adjusting for demographic factors and disease severity. ^[30]B2b In a large retrospective comparison, patients with liver disease receiving a CIWA-Ar protocol had a higher burden of alcohol use disorder and longer hospital stays than patients without liver disease. ^[142] Pregnancy may represent a high-risk context: in a small Mayo Clinic series of eight pregnant patients undergoing CIWA-Ar-based management, the median peak CIWA-Ar score was 17 (interquartile range, 14), and maternal and fetal outcomes were examined. ^[140]C Because this evidence is based on only eight cases, pregnancy-specific risk estimates remain uncertain. ^[140]C

Indicators of escalation and high-intensity care

Patients should be considered for higher-acuity monitoring when symptoms progress despite treatment, when repeated or high-dose benzodiazepine or barbiturate therapy is required, or when seizures, delirium, severe agitation, respiratory compromise, or major medical comorbidity are present. ^[65]A1c A multicenter observational study specifically evaluated CIWA-Ar scores and benzodiazepine or barbiturate doses as measures for identifying hospitalized patients who received high-intensity care. ^[144] These measures should support, not replace, bedside assessment because medication exposure may reflect institutional protocols, clinician practice, or comorbid illness as well as withdrawal severity. ^[65]A1c[144]

Phenobarbital is considered an alternative or adjunct to benzodiazepines in selected settings, but a systematic review found that the evidence base remains heterogeneous and that optimal dosing is unclear. ^[66]A1a Non-benzodiazepine approaches have also been studied, but systematic reviews report variable evidence quality and do not establish them as universal substitutes for benzodiazepines in moderate or severe AWS. ^{[68]B2a[71]A1a[32]A1a} Gabapentin has evidence as an outpatient alternative, and a hospital randomized trial evaluated a fixed-dose taper in patients with PAWSS ≥4; its use should not be interpreted as proof that seizure or delirium risk is eliminated. ^[70]B2b

Interpretation and follow-up

CIWA-Ar trajectories can help describe improvement or persistence of withdrawal, but a systematic review and meta-analysis emphasized that the score’s value as an objective measure of course and treatment response requires careful interpretation. ^[55]A1a Magnesium supplementation should not be used as a severity classifier: a multicenter randomized trial enrolled inpatients with CIWA-Ar >8 to test oral magnesium as adjunctive therapy, reflecting treatment research rather than a validated prognostic threshold. ^[52]A1b Similarly, anticonvulsant trials in moderate-to-severe inpatient AWS have evaluated symptoms, seizures, DT, and adverse events, but systematic-review evidence does not support replacing established first-line management solely on the basis of these agents. ^[32]A1a

Persistent sleep, brain, and cognitive abnormalities may occur during early abstinence even after physical withdrawal signs have resolved; these findings should not automatically be labeled ongoing acute AWS. ^[146]C Overall, risk stratification should be reassessed repeatedly, with escalation determined by the clinical trajectory, complications, comorbidities, and treatment intensity rather than by any single score. ^{[65]A1c[55]A1a[144]}

Initial emergency assessment

Alcohol withdrawal syndrome (AWS) is an emergency-department presentation that can progress to seizures, delirium tremens (DT), respiratory or autonomic instability, and death; emergency assessment should therefore identify current severity, previous withdrawal complications, concurrent intoxication or poisoning, medical illness, trauma, infection, nutritional deficiency, and psychiatric risk. The 2024 SAEM GRACE-4 guideline specifically addresses adult emergency-department patients with AWS and alcohol use disorder (AUD) using the GRADE framework, although the supplied abstract does not provide the complete individual recommendations or certainty ratings for each priority question. ^[44]A1c Recent national emergency-department data also describe AWS as a common presentation, with outcomes including admission, length of stay, and medication use changing over 2016–2023. ^[127]

Assess cognition, orientation, agitation, hallucinations, autonomic findings, tremor, nausea or vomiting, seizures, and the ability to maintain oral intake. A symptom-based instrument may assist serial assessment, but its score should not replace clinical judgment in delirium, severe psychiatric illness, major medical comorbidity, or patients unable to communicate reliably. Hospital practice remains variable: a 2025 multicenter cohort examined pharmacotherapy patterns among 245,271 hospitalized adults, while a 2024 study of electronic order sets found variation in guideline-concordant laboratory assessment, severe-withdrawal risk assessment, symptom monitoring, and treatment. ^{[111]B3b[149]}

Pharmacological treatment

Benzodiazepines remain the established first-line treatment in the direct phenobarbital evidence base, but phenobarbital is increasingly considered when benzodiazepines are unavailable, insufficient, or unsuitable. ^{[74]A1a[66]A1a} The 2024 systematic review and meta-analysis compared phenobarbital with benzodiazepines in emergency-department AWS and found that the published evidence was mixed; only eight of 59 screened abstracts met inclusion criteria. ^[73]A1a The GRACE-4 direct-evidence review similarly evaluated phenobarbital for complications, monitored-setting admission, symptom control, adverse effects, and adjunctive medication requirements. ^[74]A1a These reviews support phenobarbital as an experienced-clinician alternative or adjunct rather than evidence that it should universally replace benzodiazepines. ^{[73]A1a[74]A1a}

Phenobarbital dosing and the optimal treatment strategy remain uncertain. A broader 2023 review identified 20 studies—nine emergency-department and 11 other studies—but concluded that the level of evidence and appropriate dosing were unclear. ^[66]A1a A 2025 single-center retrospective cohort of 1,178 adults compared intravenous phenobarbital monotherapy, intravenous benzodiazepines, and combination therapy, assessing admission, emergency-department length of stay, and 72-hour return visits; its observational design limits causal interpretation. ^[113]B3b Phenobarbital should be administered only with appropriate monitoring and airway-rescue capability because sedative toxicity and additive respiratory depression are clinically important risks; the supplied studies do not establish a universally safe regimen. ^{[73]A1a[74]A1a[66]A1a}

Gabapentin may have a role in selected hospitalized patients with mild or moderate withdrawal, but evidence is insufficient to substitute routinely for benzodiazepines in acute AWS. A systematic review and meta-analysis included eight retrospective studies involving 2,030 patients and found no randomized trials addressing gabapentin replacement or reduction of benzodiazepine therapy. ^[75]A1a Baclofen is similarly investigational: in a single-blind randomized trial of 63 inpatients receiving benzodiazepine-assisted detoxification, baclofen at 30 mg/day or 60 mg/day for seven days was studied for its effect on as-needed diazepam use, but available evidence remains insufficient to support baclofen-assisted withdrawal as standard care. ^[77]A1b Vigabatrin was tested as a benzodiazepine-sparing intervention at 2 g/day for four days in a double-blind randomized trial of 120 residential-unit patients; the study evaluated diazepam requirement and dose, but this does not establish routine emergency-department use. ^[78]A1b

Oral ethanol should not be adopted as routine emergency treatment on the basis of initial service experience. A retrospective United Kingdom report described its use in patients considered high risk, including typically ≥30 units/day, severe prior withdrawal, withdrawal seizures, or DT, but observational comparisons with benzodiazepines cannot establish efficacy or safety. ^[147]C

Delirium, seizures, and psychiatric emergencies

DT requires urgent medical management, close observation, correction of contributory abnormalities, and treatment in a monitored setting; delirium also makes symptom scoring less reliable. DT has been associated with biochemical, hematological, inflammatory, and gut-permeability abnormalities, although the available biomarker study measured patients after acute resolution and does not provide a validated emergency diagnostic test. ^[148] Any seizure, persistent confusion, hallucinations, severe agitation, or rapidly escalating autonomic signs should prompt reassessment for alternative or additional causes and consideration of higher-acuity care. ^{[44]A1c[74]A1a}

Evaluate suicidality, psychosis, capacity, violence risk, and vulnerability after immediate stabilization; withdrawal-related agitation or hallucinations may coexist with intoxication, primary psychiatric illness, delirium, or medical disease. The supplied references do not provide validated suicide-risk thresholds or specific psychiatric pharmacotherapy recommendations, so psychiatric disposition should follow local emergency protocols after medical causes and delirium have been addressed. ^[44]A1c

Persistent symptoms and disposition

Symptoms can persist beyond the acute withdrawal window. Post-acute withdrawal is characterized predominantly by negative affect and may last 4–6 months or longer, with anxiety, dysphoria, anhedonia, sleep disturbance, cognitive impairment, craving, and irritability; these symptoms may increase risk of recurrent drinking. ^[16]D5 A systematic review found craving generally declined over time, with pooled Obsessive Compulsive Drinking Scale scores falling from 24.2 at baseline to 18.8 at one week, 10.3 at one month, and 9.7 at three months. ^[47]A1a Discharge should therefore include AUD treatment linkage, relapse-prevention planning, and clear return precautions when clinically appropriate. Economic evidence remains limited: a 2025 review found only eight eligible studies, emphasizing the need to balance clinical effectiveness with resource use. ^[72]B2a

Novel approaches should remain investigational. A small open-label, single-arm pilot study evaluated percutaneous auricular vagus-nerve stimulation in 30 patients with AWS, but it cannot establish clinical efficacy. ^[76]B2b Low sarcopenia index has been investigated as a predictor of pneumonia in hospitalized AWS, yet this prognostic association does not replace routine infection assessment. ^[132]C A Japanese retrospective study of 88 patients with alcoholic hepatitis highlighted the risk of missed critical events after DT, reinforcing the need for reliable follow-up and handover. ^[40]C4 A Colorado ICU analysis concerned lockdown-related non-COVID ICU utilization rather than AWS treatment and provides no basis for acute AWS recommendations. ^[145]

Definitive care addresses refractory symptoms. Loading BZD protocols may clear symptoms faster than symptom-triggered (69.6% vs 41.7% at 72h) ^[82]A1b. Adjunctive phenobarbital (10 mg/kg IV) reduces ICU admissions from 25% to 8% ^[85]A1b. Dexmedetomidine reduces 12-hour BZD needs but causes bradycardia in 35% of patients ^[87]B3b. Haloperidol is for ICU delirium but must be paired with BZDs to avoid lowering the seizure threshold ^[89]D5.

Pearl: Phenobarbital (10 mg/kg IV) significantly reduces ICU admission rates when added to BZD protocols, but routine magnesium and oxytocin do not improve clinical outcomes in AWS ^{[52]A1b[81]A1b[85]A1b}.

AWS patients are at high risk for torsade de pointes due to electrolyte shifts and QT-prolonging drugs ^[92]C4. Serial ECGs are mandatory when using antipsychotics or in patients with liver disease. Concomitant antibiotics (e.g., metronidazole ) and vasoactive support (e.g., dopamine ) exacerbate QT prolongation ^[92]C4. Aggressive correction of hypokalaemia and hypomagnesemia is required ^[92]C4.

Pearl: Hospitalized patients with AWS often have multiple silent risk factors for proarrhythmic responses; always review the medication profile for QT-prolonging drugs and correct even mild hypokalaemia immediately to prevent torsade de pointes ^[92]C4.

Purpose and urgency of assessment

Alcohol withdrawal syndrome (AWS) follows an abrupt reduction or cessation of alcohol use in an alcohol-dependent person and may progress to withdrawal seizures, delirium tremens (DT), or other clinically severe withdrawal. ^{[8]B3b[27]A1a} Severe AWS is associated with substantial morbidity and mortality, particularly when untreated; however, most hospitalized patients considered at risk do not develop severe AWS. ^[27]A1a Risk assessment should therefore identify patients requiring close observation, preventive treatment, or a higher-acuity setting without assuming that every patient with alcohol dependence will develop severe withdrawal. ^[27]A1a

Assessment should begin at presentation or admission and should be repeated during the period in which withdrawal may evolve. ^{[8]B3b[151]D[152]D} The emergency-department literature supports routine identification of patients at risk, serial monitoring of withdrawal progression and severity, and treatment according to objective assessment. ^[152]D In general hospitals, the Glasgow Assessment and Management of Alcohol guideline combines alcohol screening, risk stratification, a withdrawal scale, and treatment recommendations to support standardized care. ^[151]D

Predicting severe or complicated withdrawal

Clinical history remains central because no single sign or screening instrument reliably predicts severe AWS in every medically ill patient. ^{[27]A1a[50]B2a} Important prediction targets include DT, withdrawal seizure, and clinically diagnosed severe withdrawal. ^[27]A1a The systematic review by Wood et al. evaluated symptoms, signs, and risk-assessment tools for predicting severe AWS in hospitalized adults; its purpose was to determine which findings identify patients at risk before severe complications occur. ^[27]A1a

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed because commonly used withdrawal scales, including the Clinical Institute Withdrawal Assessment for Alcohol (CIWA), quantify current symptom severity but do not identify patients at risk of developing complicated withdrawal. ^[50]B2a PAWSS was designed to address the absence of validated prediction tools in medically ill patients and was developed through a systematic review of clinical factors followed by a pilot validation study. ^[50]B2a It should therefore be distinguished from symptom-severity instruments: a risk-prediction tool is used before or early in withdrawal, whereas a symptom scale is used to measure current manifestations and guide ongoing treatment. ^{[50]B2a[151]D[152]D}

Admission alcohol screening may contribute to risk stratification. In a retrospective case–control study of non-intensive-care medical-surgical inpatients, Pecoraro et al. examined whether the admission Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) predicted subsequent AWS. ^[8]B3b The study included patients discharged with an AWS diagnosis and distinguished patients who presented with AWS from those who developed it later during admission. ^[8]B3b Because this was an observational study and the investigators noted the need for validated hospital screening tools, AUDIT-PC should be treated as an aid to structured assessment rather than a stand-alone determinant of prophylaxis or treatment. ^[8]B3b

Other prediction approaches remain investigational. Burkhardt et al. used nested cross-validation and out-of-sample validation in two detoxification wards, comprising 389 and 805 alcohol-dependent patients, to predict moderate-to-severe withdrawal, DT, and withdrawal seizures from admission clinical, laboratory, and sociodemographic measures. ^[93]B2c The models separated mild from more severe withdrawal with statistically significant, although limited, performance; these findings support further research but do not establish machine-learning models as routine replacements for clinical assessment. ^[93]B2c

Indicators of seizure and delirium risk

Among patients already receiving treatment for moderate-to-severe AWS, delayed peaking of withdrawal severity after admission was associated with withdrawal seizures, with an odds ratio of 1.23 per 10-hour delay (95% confidence interval, 1.1–1.4; P<0.001). ^[150] A history of structural brain lesions was also a significant predictor of withdrawal seizures in the multivariable analysis. ^[150] These findings support continued observation when withdrawal severity is still increasing or has not yet reached its maximum, even when initial symptoms appear manageable. ^[150]

The Eyer et al. analysis was based on 827 inpatients treated with score-guided, symptom-triggered therapy. ^[150] Its results apply to prediction during an established withdrawal episode and should not be interpreted as a universal admission screening rule. ^[150]

Capacity, monitoring, and therapeutic setting

The therapeutic setting should match the predicted severity of withdrawal, the patient’s current symptoms, medical comorbidity, and the ability to provide repeated assessment and timely treatment. ^{[27]A1a[151]D[152]D} Patients with suspected or evolving severe withdrawal require a setting capable of frequent reassessment and management of seizures, delirium, and rapidly changing autonomic or neuropsychiatric symptoms. ^{[27]A1a[150][152]D} A delayed withdrawal peak and a history of structural brain disease warrant particular caution because they are associated with seizure risk. ^[150]

Risk stratification can be linked to treatment intensity: the Glasgow guideline uses a strategy intended to indicate fixed-dose or symptom-triggered benzodiazepine treatment, while the Glasgow Modified Alcohol Withdrawal Scale is used for symptom-triggered treatment. ^[151]D Emergency-department guidance likewise advocates standardized screening, serial alcohol-withdrawal scoring, and symptom-triggered therapy based on objective observations. ^[152]D These approaches require a patient who can be assessed repeatedly and a clinical environment able to respond when symptoms escalate. ^[151]D[152]D

Patients whose cognition, attention, or behavior prevents reliable symptom reporting may be difficult to manage with symptom-triggered scoring alone; the available references emphasize objective observation and clinical judgment but do not provide a separate validated capacity instrument for AWS. ^{[27]A1a[151]D[152]D} Capacity and safety should therefore be reassessed whenever confusion, agitation, hallucinations, seizure activity, or suspected DT develops. ^{[27]A1a[152]D}

Limits of the evidence

The evidence base is heterogeneous and includes systematic review, retrospective studies, pilot tool development, cohort re-analysis, guideline appraisal, and exploratory machine-learning research. ^{[8]B3b[27]A1a[50]B2a[93]B2c[150][151]D} The cited studies do not establish one universally validated admission tool for all medically ill patients, nor do they define a single risk threshold that determines the required level of care. ^{[8]B3b[27]A1a[50]B2a} A review of pregabalin concerns treatment of alcohol dependence rather than validated AWS risk setting or capacity assessment. ^[94]D5 A study of microsurgical reconstruction in patients with alcohol-induced mental disorders, and a study of health screening in police custody, do not provide evidence for AWS prediction, treatment setting, or capacity assessment. ^{[95]B3b[96]B2b}

Early pharmacological foundations

Alcohol withdrawal syndrome (AWS) reflects neuroadaptation to prolonged ethanol exposure, with reduced inhibitory γ-aminobutyric acid (GABA) activity and increased excitatory glutamatergic activity after chronic high-dose drinking. Withdrawal therefore produces a spectrum of autonomic, neurological, and neuropsychiatric symptoms, including seizures and delirium tremens (DT), and may occur in up to half of people who stop drinking after sustained heavy alcohol use. ^[56]A1c Historically, treatment evolved around replacing or enhancing inhibitory neurotransmission, with benzodiazepines becoming the conventional pharmacological treatment for acute AWS and the principal agents used to prevent withdrawal seizures and DT. ^{[65]A1c[70]B2b[102]A1a}

Benzodiazepine-based, symptom-triggered care

Modern inpatient management was formalized through structured assessment and symptom-triggered dosing, particularly using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), to guide benzodiazepine administration. ^{[65]A1c[70]B2b} The 2020 American Society of Addiction Medicine (ASAM) Clinical Practice Guideline, an update of the 2004 guideline focused on alcohol withdrawal delirium, addressed adults hospitalized with AWS of any severity and consolidated contemporary recommendations for assessment, monitoring, pharmacotherapy, and management of complicated withdrawal. ^[65]A1c In hospitalized patients, CIWA-directed benzodiazepines remained the usual comparator and standard approach, although symptom scales may be difficult to apply in patients with delirium, severe illness, or impaired communication. ^[70]B2b

Risk stratification has increasingly supplemented clinical judgment. A retrospective machine-learning study used admission clinical, laboratory, and sociodemographic variables to predict moderate-to-severe withdrawal, DT, and withdrawal seizures in two detoxification cohorts of 389 and 805 patients; the models separated milder from more severe outcomes with significant, although limited, predictive performance. ^[93]B2c In trauma care, a retrospective study of 1,011 adults evaluated combinations of risk conditions for AWS, recognizing that the overall proportion of trauma patients who develop AWS is low and that precise risk factors have been difficult to define. ^[31]B2b

Expansion beyond benzodiazepines

As concerns about benzodiazepine exposure, oversedation, respiratory effects, and difficult-to-control severe withdrawal grew, alternative and adjunctive therapies were investigated. Phenobarbital, a long-acting barbiturate that also enhances inhibitory GABAergic activity, has become increasingly used either with benzodiazepines or as alternative monotherapy. ^[101]D5 ASAM recommends phenobarbital in selected clinical contexts, and available evidence supports its safety and efficacy as a benzodiazepine alternative, although the overall evidence base remains limited. ^[101]D5 Dosing strategies have included front-loading followed by a taper, single-dose treatment, and symptom-triggered administration. ^[154]C Because phenobarbital has a long half-life, a retrospective ICU cohort found that a loading dose followed by no scheduled taper was evaluated against a conventional taper strategy; the pharmacokinetic rationale for automatic tapering was that the drug may self-taper, although this evidence was observational. ^[154]C

Gabapentin emerged as another non-benzodiazepine option, especially for less severe withdrawal and outpatient treatment. A randomized clinical trial in 68 adults with AUD and a history of AWS administered gabapentin 1,200 mg/day or placebo after at least 72 hours of abstinence and examined dorsal anterior cingulate GABA and glutamate concentrations as possible mechanisms underlying symptom and relapse effects. ^[97]A1b In hospitalized AWS, an open-label randomized trial of 88 adults with elevated risk for complicated withdrawal, defined as Prediction of Alcohol Withdrawal Severity Scale (PAWSS) ≥4, compared a fixed-dose gabapentin taper with CIWA-directed benzodiazepines. ^[70]B2b These studies expanded the evidence base but did not establish gabapentin as a universal replacement for benzodiazepines in severe or complicated AWS. ^{[70]B2b[97]A1b}

Other GABAergic or adjunctive strategies have produced mixed results. In a single-blind randomized trial of 63 inpatients receiving benzodiazepine-assisted detoxification, baclofen at 30 mg/day or 60 mg/day for 7 days reduced the need for additional diazepam compared with placebo, but prior evidence was considered insufficient to support baclofen-assisted detoxification as routine care. ^[77]A1b A double-blind randomized trial of 120 residential-treatment patients tested vigabatrin 2 g/day for 4 days as a diazepam-sparing agent; the prespecified outcomes were the proportion requiring diazepam and total diazepam dose. ^[78]A1b Magnesium supplementation was studied as an adjunct because hypomagnesemia may contribute to AWS severity; a multicenter, double-blind randomized trial enrolled inpatients with baseline CIWA-Ar >8 and administered oral magnesium lactate, providing 426.6 mg/day for up to 15 days, with CIWA-Ar score as the primary endpoint. ^[52]A1b

Adjunctive sedation and nonpharmacological approaches

Dexmedetomidine, an α2-adrenergic sedative, has been investigated as an alternative or adjunct to diazepam, particularly when autonomic hyperactivity and sedation are prominent. A randomized trial of 40 patients compared intravenous diazepam 5–20 mg with dexmedetomidine infusion at 0.2–0.7 μg/kg/min and assessed heart rate, blood pressure, and sedation. ^[153] A later retrospective cohort evaluated dexmedetomidine versus non-dexmedetomidine treatment in AWS using ICU stay, hospital length of stay, mortality, and readmission as outcomes, but its nonrandomized design limits causal interpretation. ^[69]B3b Transcutaneous electrical acupoint stimulation combined with diazepam was compared with sham stimulation plus diazepam in a double-blind trial of 117 men; withdrawal, anxiety, sleep, and daytime-somnolence measures improved in both groups, so the intervention was evaluated as an adjunct rather than a replacement for pharmacotherapy. ^[60]A1b

Reconsideration of ethanol and current emergency practice

Ethanol itself has periodically been proposed as treatment because it modulates both GABA-A and N-methyl-D-aspartate receptors. A 2024 systematic review critically assessed oral and intravenous ethanol for AWS and contrasted this approach with the usual benzodiazepine strategy. ^[102]A1a Subsequent UK service experience described oral ethanol prescribing for patients considered at particularly high risk, including those with likely DT, harmful consumption typically ≥30 UK units/day, previous severe withdrawal, withdrawal seizures, or DT; the evidence was retrospective and based on propensity-weighted comparisons. ^[147]C These reports represent renewed interest rather than established standard practice. ^{[102]A1a[147]C}

Contemporary emergency guidance now emphasizes evidence-based, risk-adapted care rather than a single universal regimen. The 2024 SAEM GRACE-4 guideline used the GRADE framework to address adult emergency-department patients with AWS and AUD, incorporating emergency physicians, addiction specialists, and people with lived experience. ^[44]A1c In patients with alcohol-associated hepatitis, a multinational retrospective cohort from five centers found that AWS is clinically relevant in a population already at high medical risk and examined its prevalence, predictors, management, mortality, and possible prophylaxis. ^[30]B2b Severe withdrawal also has broader consequences: a prospective cohort of inpatients undergoing withdrawal management found an association between severe AWS symptoms and suicidal behavior risk during follow-up, reinforcing the need for integrated psychiatric and addiction care. ^[103]B2b Overall, treatment has evolved from predominantly benzodiazepine-centered detoxification toward protocolized risk assessment, phenobarbital-based strategies, selected gabapentin or other adjuncts, critical-care sedation when necessary, and individualized management; however, the newer alternatives remain supported by heterogeneous and often limited evidence. ^{[44]A1c[65]A1c[101]D5}

Clinical burden and complications

Alcohol withdrawal syndrome (AWS) may progress from mild autonomic and neuropsychiatric symptoms to severe complications, including seizures, delirium tremens, severe agitation, respiratory compromise, critical-care admission, and death. ^{[74]A1a[46]A1a[66]A1a[131]} The emergency-department evidence base specifically evaluates AWS complications, symptom control, adverse effects, need for monitored care, and adjunctive medication use. ^[74]A1a The risk of complications is clinically important in hospitalized patients because AWS may itself be a reason for admission or may complicate admission for another illness. ^[128]

In patients with alcohol-associated hepatitis, AWS was investigated in a multinational retrospective cohort because its prevalence, predictors, management, and clinical impact had not been well characterized. ^[30]B2b In patients with liver disease receiving a hospital CIWA-Ar protocol, the liver-disease group had a higher prevalence of alcohol use disorder and a longer hospital length of stay than patients without liver disease; the reported median stays were 93 hours versus 69 hours, respectively. ^[142] Alcohol-associated liver disease creates particular treatment hazards because impaired drug metabolism may increase sedation and toxicity, while hepatic encephalopathy can mimic or be worsened by sedative treatment. ^[155]

Pregnancy is an uncommon but high-risk context. In a Mayo Clinic retrospective series of 8 pregnant patients treated under a CIWA-Ar protocol, the median peak CIWA-Ar score was 17 (interquartile range 14), and maternal, fetal, labor, and neonatal outcomes were examined because severe withdrawal may affect both patient and fetus. ^[140]C The small sample size limits generalization of these observations. ^[140]C

Iatrogenic harm and medication-related complications

Benzodiazepines remain standard therapy for AWS, particularly to prevent seizures and delirium tremens, but treatment may cause excessive sedation, respiratory depression, and delirium; concerns are heightened in severe withdrawal and alcohol-associated liver disease. ^{[70]B2b[136][155]} Phenobarbital has been studied as an alternative or adjunct when benzodiazepines are insufficient or unavailable, but systematic reviews emphasize that the evidence is heterogeneous and that optimal dosing and comparative safety remain uncertain. ^{[74]A1a[46]A1a[66]A1a}

The available phenobarbital literature includes emergency-department, intensive-care, trauma, and surgical-trauma populations. ^[66]A1a A systematic review and meta-analysis compared phenobarbital-based strategies with benzodiazepines or no intervention using outcomes that included complications, monitored-setting admission, symptom control, adverse effects, and adjunctive medication use. ^{[74]A1a[46]A1a} Trauma studies evaluated phenobarbital monotherapy or low-dose oral regimens against benzodiazepine-based protocols because benzodiazepine-associated delirium and benzodiazepine-refractory withdrawal are concerns; these retrospective data do not establish superiority. ^[136] In critically ill surgical-trauma patients, phenobarbital therapy was assessed for post-treatment severe agitation, delirium tremens, and seizures as AWS-related complications. ^[131]

A 2026 retrospective ICU analysis specifically examined phenobarbital versus benzodiazepines in severe AWS among patients with alcohol-associated liver disease, using inverse-probability treatment weighting to balance baseline characteristics. ^[155] Its rationale included concerns about drug shortages, oversedation, hepatic encephalopathy, and respiratory depression, but retrospective treatment allocation limits causal interpretation. ^[155] Dexmedetomidine has also been used as an adjunctive sedative to reduce apparent withdrawal symptoms and CIWA-Ar scores; a retrospective cohort examined ICU stay, hospital stay, mortality, and readmission in patients treated with or without dexmedetomidine. ^[69]B3b Because dexmedetomidine may improve observable agitation without correcting the underlying withdrawal pathophysiology, symptom-score improvement should not by itself be interpreted as prevention of seizures or delirium tremens. ^{[69]B3b[74]A1a}

Gabapentin is an evidence-based option for outpatient AWS in selected patients, but its role in hospitalized AWS remains less established. ^{[70]B2b[75]A1a} An open-label randomized trial enrolled 88 adults at risk for complicated withdrawal, defined as PAWSS ≥4, and compared a fixed-dose gabapentin taper with CIWA-directed benzodiazepines. ^[70]B2b A systematic review and meta-analysis of 8 retrospective studies involving 2,030 patients examined symptom resolution, benzodiazepine exposure, serious withdrawal-related complications, and length of stay; the evidence was observational and did not provide the certainty of randomized comparative data. ^[75]A1a

Patient factors and systems-related harm

Age and sex may influence AWS presentation and hospital course. A cohort of 16,190 hospitalizations, representing 10,092 patients aged ≥21 years, included 30.2% women and examined differences across four age groups, with ages 40–64 years used as the reference group. ^[36]B2b In a separate tertiary alcohol-related disease-unit cohort of 907 patients, 238 (26.2%) were female; investigators compared psychiatric manifestations, comorbidities, and AWS severity by sex. ^[125]

Care-process variation can create iatrogenic risk. A multicenter review of hospital electronic order sets assessed concordance with guidance in laboratory evaluation, severe-AWS risk assessment, symptom assessment, treatment, and identification or management of associated conditions. ^[149] Protocol evaluation has also included a modified MINDS-based symptom protocol on general medical wards, where CIWA-Ar may be difficult to apply when patients are delirious, intubated, cognitively impaired, or unable to communicate reliably. ^[130] In an ICU sedation study, AWS was specifically excluded from the analytic cohort, underscoring that sedation findings from general mechanically ventilated populations should not be extrapolated to AWS. ^[141]C

Discharge treatment may also be inequitable: a 2016–2024 academic-center study examined race, ethnicity, and language differences in prescriptions for medications for alcohol use disorder after AWS hospitalization. ^[37]B2b Missed opportunities to initiate evidence-based AUD medication may increase recurrence of withdrawal and related morbidity, although the cited study evaluated prescribing disparities rather than subsequent clinical outcomes. ^[37]B2b

Overall trajectory

Alcohol withdrawal syndrome (AWS) has a heterogeneous course. Most patients who develop withdrawal experience mild symptoms, whereas a smaller proportion develop withdrawal seizures, delirium tremens (DT), or another severe withdrawal syndrome requiring hospital-level care ^[137]. The maximum withdrawal score is clinically prognostic: in a retrospective cohort of 2,464 hospital stays, higher maximum Wetterling AWS scores were associated with longer hospitalization and increased in-hospital mortality; the analysis also examined scores during the first 3 days of withdrawal, supporting early severity assessment as a marker of subsequent clinical risk ^[58]B3b.

A systematic review and meta-analysis of studies using the Clinical Institute Withdrawal Assessment for Alcohol–Revised (CIWA-Ar) found that aggregated CIWA-Ar scores generally follow the clinical course of AWS and can be used to monitor response over time ^[55]A1a. However, CIWA-Ar-based evidence is derived from treated populations and should not be interpreted as a precise untreated natural-history curve ^[55]A1a. A machine-learning study of 1,194 alcohol-dependent patients from two detoxification wards showed that admission clinical, laboratory, and sociodemographic variables could distinguish mild from more severe withdrawal and were evaluated for prediction of DT and withdrawal seizures, although predictive performance was described as significant but limited rather than definitive ^[93]B2c. The Alcohol Withdrawal Triage Tool was similarly derived and validated using objective emergency-department variables to predict severe AWS, defined as DT, seizure, or high benzodiazepine requirement; its rationale reflects that most withdrawal is mild but a clinically important minority progresses to severe disease ^[137].

Hospital course and prognostic modifiers

In a national Veterans Health Administration cohort of 6,938 medical inpatients treated with benzodiazepines, initial strategies were symptom-triggered in 40.8%, fixed-dose in 41.9%, and front-loading in 17.3% ^[5]B2c. This large observational study evaluated cumulative benzodiazepine exposure, intensive-care use, and intubation in relation to patient, facility, and dosing-strategy characteristics, demonstrating substantial variation in inpatient treatment and resource use rather than a uniform hospital course ^[5]B2c. In severe AWS, a pre–post study defined severe disease as requiring more than 30 mg of diazepam and evaluated whether administering more than 50% of the total diazepam dose during the first 24 hours influenced length of stay; the study was specifically designed to test whether early focused treatment could shorten hospitalization ^[157]C.

Comorbidity may materially worsen prognosis. In a multinational retrospective cohort of patients hospitalized with alcohol-associated hepatitis, investigators assessed AWS prevalence, predictors, management, and mortality while adjusting for demographic characteristics and disease severity ^[30]B2b. In a Japanese retrospective series of 88 patients with alcoholic hepatitis, outcomes were examined according to acute-on-chronic liver failure, DT, risk factors, and subsequent events; the report highlighted the possibility that loss of contact after DT may contribute to missed critical events ^[40]C4. These studies support close monitoring when AWS occurs with alcohol-associated liver disease, although they do not establish a universal mortality estimate ^{[30]B2b[40]C4}.

Treatment-related effects on the course

Evidence comparing pharmacologic strategies does not demonstrate a consistent alternative to benzodiazepines for symptom reduction. A network meta-analysis of 41 randomized studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between benzodiazepines and other medications or combinations; anticonvulsant plus benzodiazepine therapy was associated with a mean ICU-stay reduction of 1.71 days (95% CI, 0.59–2.82 days shorter) ^[57]A1a.

Small randomized trials in uncomplicated or residential withdrawal settings evaluated benzodiazepine-sparing approaches, including intranasal oxytocin with symptom-triggered oxazepam over 3 days, baclofen versus a decremented 9-day chlordiazepoxide regimen, vigabatrin for 4 days, and transcutaneous electrical acupoint stimulation with diazepam for 14 days ^{[81]A1b[107]A1b[78]A1b[60]A1b}. These studies assessed withdrawal symptoms, benzodiazepine exposure, or patient-reported outcomes, but their small samples and treatment-unit settings limit conclusions about long-term prognosis ^{[81]A1b[107]A1b[78]A1b[60]A1b}. In the vigabatrin trial, the prespecified primary outcome was whether diazepam was required and the secondary outcome was total diazepam dose ^[78]A1b.

For ICU-level AWS, randomized evidence evaluated dexmedetomidine added to symptom-triggered benzodiazepines in 72 patients, targeting arousable sedation without respiratory depression; this addresses control of autonomic hyperactivity and sedation requirements rather than the underlying duration of withdrawal ^[156]. Retrospective ICU and hospital studies evaluated symptom-triggered phenobarbital, phenobarbital plus benzodiazepines, and dexmedetomidine plus benzodiazepines in relation to AWS resolution, length of stay, mechanical ventilation, and complications, but their nonrandomized designs and inconsistent results limit causal prognostic inference ^{[158][114]B3b[126]}. A retrospective comparison of clomethiazole and diazepam in a matched sample of 152 intensive-care psychiatric patients found no significant difference in mean daily symptom reduction, indicating broadly comparable short-term symptom trajectories in that selected population ^[159]. A psychiatric-inpatient protocol evaluation and a randomized TEAS study likewise reported treatment-course outcomes, but neither establishes the natural history of untreated AWS ^[135][60]A1b.

Practical prognosis

Severity during the early withdrawal period, especially the emergence of seizures, DT, high symptom scores, escalating sedative requirements, or ICU-level treatment, identifies patients at risk for a more complicated course ^{[58]B3b[93]B2c[137]}. Available evidence supports serial clinical assessment and timely escalation of monitoring and treatment, while recognizing that treatment studies primarily describe symptom control and resource utilization rather than recurrence, sustained abstinence, or long-term mortality ^{[5]B2c[55]A1a[57]A1a}.

Scope and evidence limitations

Alcohol withdrawal syndrome (AWS) in pregnancy is substantially under-researched in the supplied evidence base. The pregnancy-specific study identified only 8 pregnant patients treated under a Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) protocol during 2019–2022, and reported a median peak CIWA-Ar score of 17 (interquartile range, 14), indicating clinically significant withdrawal in this small cohort.^[140]C The study reviewed pregnancy, labour, and neonatal records for alcohol-related complications and outcomes, but its retrospective design and very small sample preclude reliable estimates of incidence, comparative treatment efficacy, or medication safety.^[140]C No supplied reference directly evaluates psychotherapy, psychiatric consultation models, relapse-prevention medication, or postnatal mental-health outcomes specifically in pregnant or postpartum patients; therefore, perinatal psychiatric management must be individualised and coordinated with obstetric, neonatal, addiction, and medical teams.^[140]C

Pregnancy and early postpartum AWS

Pregnant or recently postpartum patients with suspected AWS require prompt assessment because severe withdrawal can threaten maternal stability and may affect fetal or neonatal outcomes; however, the supplied pregnancy study does not establish which pharmacological regimen is safest or most effective.^[140]C CIWA-Ar scores should be interpreted in clinical context rather than used as the sole determinant of treatment, particularly when symptoms may reflect obstetric disease, infection, pain, medication effects, or other medical complications.^[140]C[166] The CIWA-Ar has recognised limitations outside validated detoxification settings, and postoperative physiological responses and systemic inflammatory response syndrome can produce overlapping signs and potentially false-positive scores.^[166]

Benzodiazepines remain the principal comparator and established inpatient treatment standard in the anti-seizure medication (ASM) evidence base, but the systematic review included adults older than 18 years and does not provide pregnancy-specific efficacy or safety conclusions.^[110]A1a That review identified 24 randomised controlled trials involving 2,223 participants and evaluated seizures, delirium, CIWA-Ar outcomes, and tolerability; its findings therefore cannot be assumed to apply to fetuses, neonates, or breastfeeding infants.^[110]A1a Phenobarbital and other ASMs should not be selected as pregnancy-specific alternatives solely on the basis of adult AWS data.^{[110]A1a[113]B3b[114]B3b[154]C[164][165][167]C}

The pregnancy-specific evidence is observational and too limited to define thresholds for intensive care, fetal monitoring, delivery planning, or neonatal observation.^[140]C Management should therefore prioritise maternal stabilisation, prevention and treatment of seizures or delirium, correction of coexisting medical abnormalities, and early obstetric and neonatal involvement, while explicitly documenting the risk–benefit reasoning for sedative treatment.^[140]C The supplied references do not establish a standard benzodiazepine, dose, taper, phenobarbital regimen, or breastfeeding protocol for perinatal AWS.^{[110]A1a[140]C}

Psychiatric and perinatal care

AWS should be distinguished from primary anxiety, panic, mania, psychosis, delirium due to another medical cause, and substance intoxication or withdrawal, because the available assessment data are not specific to psychiatric illness.^[140]C[166] In patients with altered mental status, seizures, fever, focal neurological findings, or an atypical course, clinicians should investigate alternative diagnoses rather than escalating sedatives solely in response to a high withdrawal score.^[48]B2b[166] Alcoholic patients with community-acquired bacterial meningitis had seizures at presentation in 18% of episodes, and pneumonia co-occurred in 23%, illustrating the importance of considering serious neurological and infectious mimics.^[48]B2b

A perinatal psychiatric assessment should include alcohol-use severity, previous withdrawal seizures or delirium, suicidality, psychosis, trauma, domestic or social risks, prenatal care, other substance exposure, medication history, and the patient’s capacity to participate in treatment; the supplied references support the need for broader clinical assessment but do not validate a pregnancy-specific psychiatric instrument.^[140]C[166] Screening and treatment planning should continue after the acute withdrawal episode because the cited studies primarily address acute medical outcomes and do not establish long-term psychiatric or parenting outcomes.^{[110]A1a[140]C}

Other high-risk populations relevant to perinatal services

Patients with neurological injury require particular caution because both AWS and sedative therapy can obscure neurological deterioration. In a retrospective ICU cohort of patients with primary neurological injuries, phenobarbital was compared with symptom-triggered benzodiazepines, with oversedation defined using a Richmond Agitation-Sedation Scale-based outcome; this evidence is observational and does not establish superiority or pregnancy safety.^[164] Studies of severe AWS have also evaluated phenobarbital alone or as an adjunct to lorazepam, including ICU and emergency-department cohorts, but their retrospective designs and adult populations limit generalisability to pregnancy.^{[113]B3b[114]B3b[154]C[165][167]C}

Liver disease and severe alcohol-related illness may complicate withdrawal management. A Japanese hospital study of 88 patients with alcoholic hepatitis examined acute-on-chronic liver failure, delirium tremens, risk factors, and outcomes, but the supplied abstract does not provide pregnancy-specific findings or a validated medication strategy.^[40]C4 Low serum magnesium was associated with one-year mortality in a retrospective AWS cohort: among 380 analysed patients, 64 (17%) died within one year.^[160] These findings support careful medical assessment and correction of clinically important abnormalities, but they do not prove that magnesium replacement or vitamin supplementation prevents AWS complications.^[160][161]C

Practical implications

Because pregnancy-specific evidence is limited to a very small retrospective series, treatment should use the minimum effective sedative exposure while avoiding undertreatment of severe AWS, with continuous reassessment of maternal mental status, respiratory function, seizure risk, hydration, electrolytes, and obstetric status.^[140]C Adult evidence suggests that phenobarbital use is being studied as monotherapy, adjunctive therapy, or with and without tapering, but current comparative data are retrospective or otherwise not pregnancy-specific.^{[113]B3b[114]B3b[154]C[165][167]C} Any use of phenobarbital or an ASM in pregnancy should therefore be specialist-led, with neonatal planning and explicit acknowledgement of uncertainty.^{[110]A1a[140]C}

Prevention principles

Alcohol withdrawal syndrome (AWS) is potentially life-threatening and may complicate hospital admission, particularly when alcohol use is abruptly reduced or stopped. Prevention therefore depends on identifying alcohol use and withdrawal risk at presentation, distinguishing patients suitable for outpatient care from those requiring monitored inpatient management, and initiating structured assessment before clinically significant withdrawal develops. ^{[118]D5[170]D} AWS is also a recurrent and preventable cause of hospitalization; a 2024 primary-care cohort evaluated its incidence using electronic health records, claims data, and annual standardized alcohol screening, underscoring the value of routine alcohol-use identification in primary care. ^[128]

Screening for alcohol use and withdrawal risk

Routine screening should use a validated alcohol-use instrument where available, such as the Alcohol Use Disorders Identification Test (AUDIT); AUDIT has also been identified as a tool for detecting alcohol use disorder in patients with alcohol-associated liver disease. ^[170]D In hospitalized medical-surgical patients, the admission Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) was evaluated for predicting AWS occurring later during admission, although the study noted that hospitals lacked a universally validated withdrawal-risk tool at that time. ^[8]B3b

Risk assessment should include the patient’s history of complicated withdrawal, including delirium tremens or withdrawal seizures, the severity and pattern of alcohol consumption, recent reduction or cessation, current withdrawal findings, medical comorbidity, and relevant laboratory abnormalities. ^{[35]B3b[50]B2a[115]A1a[171]D} The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed specifically to identify patients at risk for complicated AWS, because symptom-severity instruments such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) quantify current withdrawal but do not predict future complicated withdrawal. ^[50]B2a PAWSS was initially supported by a systematic review of clinical risk factors and a pilot validation study; its predictive role should be interpreted in the context of the study population and local validation. ^[50]B2a

Additional risk-stratification approaches remain investigational. A machine-learning analysis using admission clinical, blood-derived, and sociodemographic variables in 1,194 patients from two detoxification wards demonstrated significant separation of mild from more severe withdrawal outcomes and attempted prediction of delirium tremens and withdrawal seizures. ^[93]B2c In trauma patients, a retrospective study of 1,011 adults investigated combinations of admission risk conditions, including blood alcohol concentration and heavy drinking, to estimate the probability of AWS; these findings support multifactorial rather than single-variable screening but do not establish a universal prediction rule. ^[31]B2b A case-control study of 382 patients with severe AWS and 382 controls evaluated 24 potential risk variables, reflecting the ongoing effort to define reliable predictors in acute hospitals. ^[35]B3b

Early intervention in hospital

Hospitals should use a written, standardized pathway linking risk assessment, repeated symptom assessment, treatment thresholds, monitoring, and escalation. In critically ill patients, AWS and delirium tremens are common clinical problems, but a systematic review found that no current practice guideline specifically addressed all aspects of ICU prevention and management. ^[115]A1a A 2024 review of electronic health-record order sets examined concordance with guideline-based laboratory assessment, severe-withdrawal risk assessment, symptom assessment, and treatment; variation between hospital organizations indicates that order sets should be audited rather than assumed to be guideline-concordant. ^[149]

A retrospective six-year cohort evaluated universal noncritical-care AUD screening with PAWSS, followed by Glasgow Modified Alcohol Withdrawal Scale assessment and protocolized medication for at-risk patients. This intervention was designed to reduce length of stay, benzodiazepine exposure, and AWS-related adverse events; because it was retrospective, its observed effects should not be treated as definitive proof of causality. ^[143] Prevention strategies must also address thiamine and nutritional risk, liver disease, seizures, delirium, electrolyte abnormalities, depression, polysubstance use, and other coexisting problems through coordinated multidisciplinary care. ^{[118]D5[170]D}

Choice of setting and outpatient detoxification

Outpatient detoxification is appropriate only after eligibility screening and when reliable daily or otherwise close follow-up, clinical stability, and absence of major risk factors for complicated withdrawal can be ensured. ^[118]D5[168] An open-label observational study evaluated levetiracetam, with diazepam available as rescue medication, in screened outpatients who were seen daily for five days; a separate nine-patient case series evaluated flexible-dose levetiracetam plus tiapride for a maximum of seven days, with daily Alcohol Withdrawal Syndrome Scale assessment. ^[168][117]C4 These small, uncontrolled studies indicate feasibility in selected patients but do not establish these regimens as standard preventive therapy.

Benzodiazepines remain central to supervised withdrawal treatment. In a randomized, double-blind trial of 100 men with moderately severe, uncomplicated inpatient withdrawal, fixed-dose lorazepam and chlordiazepoxide schedules were directly compared over eight treatment days. ^[116]A1b In patients with alcohol-associated liver disease, treatment should combine standardized withdrawal scoring with symptom-triggered benzodiazepine administration and an appropriately monitored setting when severity warrants it. ^[170]D

Evidence for non-benzodiazepine preventive or early-intervention pharmacotherapy is limited or context-specific. Cochrane reviews evaluated baclofen for AWS in 2011 and 2013, but these reviews should not be interpreted as establishing baclofen as a routine substitute for benzodiazepines. ^{[14]A1a[13]A1a} Phenobarbital has been studied for prevention in trauma patients, including a matched comparison with symptom-triggered therapy, but the available study design and limited prevention evidence do not support universal prophylaxis. ^[171]D Economic evidence is similarly limited: a 2025 systematic review screened 6,347 records and included only eight studies, highlighting the need to consider both clinical effectiveness and resource use when implementing AWS pathways. ^[72]B2a

Practical escalation thresholds

Patients with a history of delirium tremens or withdrawal seizures, substantial medical or psychiatric comorbidity, uncertain support or follow-up, severe current symptoms, or suspected complicated withdrawal should be managed in a setting capable of frequent reassessment and rapid escalation. ^{[35]B3b[50]B2a[115]A1a[118]D5[170]D} Outpatient treatment should be discontinued and inpatient evaluation arranged if symptoms progress, monitoring becomes unreliable, oral treatment is not tolerated, seizures or delirium occur, or vital-sign instability develops. ^{[118]D5[170]D} These safety thresholds reflect the potentially rapid progression and multisystem complications of AWS, rather than a single score alone. ^{[50]B2a[115]A1a}